3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
NET
1
Endocrine
1
Conditions
Breast Neoplasms
39
Ovarian Neoplasms
32
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Fallopian Tube Neoplasms
16
Neoplasm Metastasis
14
Pancreatic Neoplasms
9
Neoplasms
9
Endometrial Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Small Cell Lung Carcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Glioma
6
Stomach Neoplasms
5
Sarcoma
5
Lung Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Metastatic Castration-resistant Prostate Cancer
4
Carcinoma, Ovarian Epithelial
4
Solid Tumors
3
Recurrence
3
Osteosarcoma
3
Neuroendocrine Tumors
3
Lymphoma, Non-Hodgkin
3
Cholangiocarcinoma
3
Urinary Bladder Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Interventions
pembrolizumab
4
Cyclophosphamide
4
Radiotherapy
3
Cisplatin
3
fludarabine
2
Doxorubicin
2
Carboplatin
2
zimberelimab
1
olaparib
1
lenvatinib
1
envafolimab
1
avelumab
1
Thymectomy
1
Taxes
1
Sunitinib
1
Robotic Surgical Procedures
1
Ramucirumab
1
Radiotherapy, Adjuvant
1
Paclitaxel
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Etoposide
1
Drug Therapy
1
Chemoradiotherapy
1
Cetuximab
1
AP 1903 reagent
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymoma
×
olaparib
×
1 year
×
Clear all
NCT04375267
2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1
Completed
18 enrolled